Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

NCT06239467 is registered in ClinicalTrials.gov with OnKure, Inc. as lead sponsor.

NCT NCT06239467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
Lead sponsor
OnKure, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 26, 2024
Completion date
August 1, 2027
Enrollment
200 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumors, breast cancer, pi3k gene mutation